Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 9;5(11):1856-1869.
doi: 10.1016/j.ekir.2020.08.031. eCollection 2020 Nov.

Dialysis-Induced Cardiovascular and Multiorgan Morbidity

Affiliations
Review

Dialysis-Induced Cardiovascular and Multiorgan Morbidity

Bernard Canaud et al. Kidney Int Rep. .

Abstract

Hemodialysis has saved many lives, albeit with significant residual mortality. Although poor outcomes may reflect advanced age and comorbid conditions, hemodialysis per se may harm patients, contributing to morbidity and perhaps mortality. Systemic circulatory "stress" resulting from hemodialysis treatment schedule may act as a disease modifier, resulting in a multiorgan injury superimposed on preexistent comorbidities. New functional intradialytic imaging (i.e., echocardiography, cardiac magnetic resonance imaging [MRI]) and kinetic of specific cardiac biomarkers (i.e., Troponin I) have clearly documented this additional source of end-organ damage. In this context, several factors resulting from patient-hemodialysis interaction and/or patient management have been identified. Intradialytic hypovolemia, hypotensive episodes, hypoxemia, solutes, and electrolyte fluxes as well as cardiac arrhythmias are among the contributing factors to systemic circulatory stress that are induced by hemodialysis. Additionally, these factors contribute to patients' symptom burden, impair cognitive function, and finally have a negative impact on patients' perception and quality of life. In this review, we summarize the adverse systemic effects of current intermittent hemodialysis therapy, their pathophysiologic consequences, review the evidence for interventions that are cardioprotective, and explore new approaches that may further reduce the systemic burden of hemodialysis. These include improved biocompatible materials, smart dialysis machines that automatically may control the fluxes of solutes and electrolytes, volume and hemodynamic control, health trackers, and potentially disruptive technologies facilitating a more personalized medicine approach.

Keywords: circulatory stress systemic stress; hidden risks of dialysis; intradialytic morbidity; personalized medicine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Dialysis-induced systemic stress (DISS) acting as disease modifier and resulting in a multiorgan injury superimposed on preexistent comorbidities and affecting outcomes.
Figure 2
Figure 2
Various actions envisaged to personalize patient care and reduce dialysis-induced systemic stress (DISS). AA, amino acids; AI, artificial intelligence; CVD, cardiovascular disease; IWAK, implantable and wearable artificial kidney; RRT, renal replacement therapy; Vit, vitamins; WAK, wearable artificial kidney.

Similar articles

Cited by

References

    1. Liyanage T., Ninomiya T., Jha V. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385:1975–1982. - PubMed
    1. Thomas B., Wulf S., Bikbov B. Maintenance dialysis throughout the world in years 1990 and 2010. J Am Soc Nephrol. 2015;26:2621–2633. - PMC - PubMed
    1. Robinson B.M., Akizawa T., Jager K.J. Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet. 2016;388:294–306. - PMC - PubMed
    1. Lopes A.A., Bragg-Gresham J.L., Satayathum S. Health-related quality of life and associated outcomes among hemodialysis patients of different ethnicities in the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS) Am J Kidney Dis. 2003;41:605–615. - PubMed
    1. Couillerot-Peyrondet A.L., Sambuc C., Sainsaulieu Y. A comprehensive approach to assess the costs of renal replacement therapy for end-stage renal disease in France: the importance of age, diabetes status, and clinical events. Eur J Health Econ. 2017;18:459–469. - PubMed

LinkOut - more resources